Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

by Avet-Loiseau, H., Bahlis, N.J, Cavo, M., Dimopoulos, M.A, Facon, T., Heuck, C., Hungria, V., Iida, S., Kobos, R., Krevvata, M., Kumar, S., Mateos, M.-V, Moreau, P., Munshi, N., Paiva, B., Perrot, A., Plesner, T., Qi, M., San-Miguel, J., Sonneveld, P., Spencer, A., Sun, S., Ukropec, J., Usmani, S.Z, van de Donk, N.W.C.J, Wang, J., Weisel, K.
Published 2022

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

by Anderson, L.D., Jr, Beksac, M., Corso, A., Dimopoulos, M., Dürig, J., Engelhardt, M., Galli, M., Grote, L., Jenner, M., Jiang, R., Kanate, A.S, Larocca, A., Liberati, A.M, Lindsay, J., Moreau, P., Oriol, A., Pavic, M., Peluso, T., Richardson, P.G, Robak, P., Rodriguez-Otero, P., Salomo, M., Schjesvold, F., Sonneveld, P., Vural, F., Weisel, K., White, D., Yagci, M.
Published 2022